Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Growth Metrics

Others

Bioregenx (BRGX) Capital Expenditures (2024 - 2025)

Bioregenx has reported Capital Expenditures over the past 2 years, most recently at $3057.0 for Q4 2025.

For Q4 2025, Capital Expenditures changed N/A year-over-year to $3057.0; the TTM value through Dec 2025 reached $9057.0, down 95.22%, while the annual FY2025 figure was $9057.0, 95.22% down from the prior year.
Capital Expenditures for Q4 2025 was $3057.0 at Bioregenx, down from $6000.0 in the prior quarter.
Over five years, Capital Expenditures peaked at $189390.0 in Q1 2024 and troughed at $3057.0 in Q4 2025.